

*10. H. M. Hoopes, M.V.
would you like to see these reports as they become available?
Zed*

Chemical Manufacturers Association

Record of Meeting

VINYLLIDENE CHLORIDE PROJECT PANEL

November 15, 1979

CMA Offices, Room 404

Washington, D. C.

Chairman W. H. Patterson called the meeting to order at 10:30 a.m. Present were the following:

MEMBERS PRESENT

W. A. Patterson, Chairman
W. C. Bachtel (For M. N. Johnson)
Z. G. Bell, Jr.
J. R. McDonough
J. M. Norris
R. J. Turner
P. J. Vanderhorst

W. R. Grace & Company
BFGoodrich Company
PPG Industries, Inc.
Tennessee Eastman Company
Dow Chemical U.S.A.
Morton Chemical Company
E. I. du Pont de Nemours
& Company

R. P. Schumacher

CMA Staff

PRESENT BY INVITATION

W. R. Hoopes
A. M. Kaplan

J. M. Soper
K. M. Thomka

W. R. Grace & Company
E. I. du Pont de Nemours
& Company
Dow Chemical U.S.A.
Dow Chemical U.S.A.

MEMBERS ABSENT

P. E. Berteau
H. A. Cantor

A. Knoishi

S. Motegi
L. Rapoport
J. M. Smith

Monsanto Company
Union Chemicals Division of
Union Oil Company of
California
Kureha Chemical Industry
Company Limited
Asahi-Dow Limited
Olin Corporation
Rohm and Haas Company

RECEIVED

DEC 10 1979

Environmental Affairs

SL 027696

1.0 Record of Last Meeting

The Panel approved the March 6, 1979 Record of Meeting with the following typographical error in Section 2 noted:
D. J. M. Norris should read Dr. J. M. Norris.

2.0 Finances

A review of the November, 1979 financial statement covering both Phase I and Phase II research, indicates that approximately \$8,000 remains to cover administrative costs. The Panel has \$15,000 from the contingency fund which it can commit and management contacts have \$33,000 available for commitment.

3.0 Midwest Research Institute (MRI) Report

Dr. J. M. Norris reviewed the last MRI report, Additional Evaluation of the Environmental Toxicants Vinyl Chloride (VC) and Vinylidene Chloride (VDC). This report contains data from two studies, one where the animals were sacrificed when exposure was terminated and the other where they were sacrificed one year post exposure. The studies suffer from a lack of technical clarity and animal accountability. Discrepancies in the data appear between the progress reports and the final report as well. Dr. Norris indicated that she may have an opportunity to discuss this study with Dr. C. C. Lee, chief investigator, sometime in December.

4.0 Sittenfield Study

K. M. Thomka presented data from this Dow-sponsored study which examined the VDC-exposed population cited in the Current Intelligence Bulletin #28. According to the Bulletin there are 6,500 definite and 58,000 probable workers exposed to the compound.

The study data indicate considerably fewer are exposed.

<u>Population Groups</u>	<u>Number of Workers</u>	<u>Exposure (TWA)</u>	<u>Estimated %Total Pop.</u>
Manufacturing	523	0.2-2.43 ppm	100%
Processors	803-813	0.1-2.8 ppm	95%
Converters	<u>1649-1836</u>	ND*-0.18 ppm	95%
Total	2975-3172		

*ND @ 0.02 ppm

The study concluded that a suitable cohort population to perform an epidemiology study was not available. Too few workers have been exposed to VDC for a sufficient number of years.

<u>Number of Years Working with VDC</u>	<u>Number of Workers</u>	
	<u>Manufacturing Process</u>	<u>Polymerization Operation</u>
15	30	80
10-15	75	130
5-10	84	140
3-5	67	123
1-3	136	210
1	119	57
	511	740
	Totals	

Mr. Thomka state that a final report can be expected in the near future.

5.0 Current Intelligence Bulletin #28 Evaluation

J. M. Norris reviewed the tumor incidence data for various tissues which the CIB described as being sites of VDC-induced tumors. Statistical evaluation of the data does not support the view that exposure to VDC produces tumors in these tissues. The kidney is possibly an exception, since Maltoni's data show an increased incidence rate for adenocarcinomas in male mice exposed to 25 ppm compared to controls. However, this data did not show a dose-response relationship and they were not reproducible in a second similar group.

Statements about epidemiology and mutagenicity studies do not accurately represent the experimental data obtained. Also, the adverse effects of VDC-exposed workers reported in the CIB do not reflect general workplace experience with the chemical.

6.0 EPA Carcinogen Assessment Group (CAG) Evaluation

In addition to the conclusions reached in the CIB, the CAG group stated that the Maltoni study demonstrated a significant increase in mammary gland fibromas and carcinomas. J. M. Norris presented the available data from this study which failed to show a consistent dose-response relationship in tumor induction.

7.0 Maltoni Inhalation Study

The Panel discussed the essential need of obtaining the complete Maltoni data in order to fully assess the toxicological effects of long-term exposure to VDC. It AGREED to contact

Dr. Andre Collard of Solvay and to ask him for either the final Maltoni report or a copy of the completed animal data. CMA will coordinate this request.

8.0 Election of a New Chairman and Vice Chairman

The Nominating Committee of J.M. Norris and J. R. McDonough reported that Z. G. Bell and R. J. Turner have agreed to serve as chairman and vice chairman of the Panel, respectively. With no additional nominations from the floor, Z. G. Bell and R. J. Turner were elected to their respective offices.

9.0 Status of Subcommittees

W.A. Patterson suggested that the Panel consider dissolving the four inactive subcommittees. After discussing the possibility of using them in the future if the Panel pursues an advocacy role, the members AGREED to maintain them as they presently stand.

10.0 Advocacy Actions

Panel members discussed their views on what role the Panel under a CMA umbrella should take in the area of advocacy. R. P. Schumacher stated that any position they wanted to develop and support through CMA must be based on scientific data. In addition, the Purpose Section of the Panel's Charter would have to be amended to include an advocacy role. This in turn would have to be approved by the management contacts of the companies represented. The final step would be to have it approved by the Special Projects Advisory Group of CMA.

The Panel APPROVED to have R. P. Schumacher draft an amendment to the Purpose Section of the Charter which then would be reviewed by the Panel.

11.0 Z. G. Bell expressed the Panel's appreciation of the service rendered by W.A. Patterson as Chairman of the Panel.

The next meeting will be called by the chairman.

Dr. Bell adjourned the meeting at 3:15 p.m.

Randal P. Schumacher

Randal P. Schumacher
Temporary Project Administrator
Vinylidene Chloride

RPS:tab

Record Subject to Approval
December 10, 1979